Editas Medicine Inc.

1.53
-0.08 (-4.97%)
At close: Apr 25, 2025, 3:59 PM
1.55
0.98%
After-hours: Apr 25, 2025, 05:46 PM EDT

Company Description

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.

It develops a proprietary gene editing platform based on CRISPR technology.

The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.

It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia.

In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease.

It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio.

The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013.

Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine Inc.
Editas Medicine Inc. logo
Country United States
IPO Date Feb 3, 2016
Industry Biotechnology
Sector Healthcare
Employees 246
CEO Dr. Gilmore O'Neill M.D.

Contact Details

Address:
11 Hurley Street
Cambridge, Massachusetts
United States
Website https://www.editasmedicine.com

Stock Details

Ticker Symbol EDIT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001650664
CUSIP Number 28106W103
ISIN Number US28106W1036
Employer ID 46-4097528
SIC Code 2836

Key Executives

Name Position
Dr. Gilmore O'Neill M.D. President, Chief Executive Officer & Director
Amy Parison Senior Vice President & Chief Financial Officer
Cristi Barnett Senior Vice President of Corporate Communications & Investor Relations
Damien Grierson J.D. Senior Vice President, Head of Legal & Corporate Secretary
Dr. Feng Zhang Ph.D. Co-Founder & Scientific Advisory Board Member
Dr. George McDonald Church Ph.D. Co-Founder & Scientific Advisory Board Member
Dr. Linda C. Burkly Ph.D. Executive Vice President & Chief Scientific Officer
Frank Panaccio Senior Vice President & Head of Business Development
Gregory Whitehead Executive Vice President and Chief Technical & Quality Officer
Linea Aspesi Executive Vice President & Chief Administration Officer

Latest SEC Filings

Date Type Title
Apr 17, 2025 SCHEDULE 13G/A [Amend] Filing
Apr 15, 2025 ARS Filing
Apr 15, 2025 DEFA14A Filing
Apr 15, 2025 DEF 14A Filing
Apr 08, 2025 4 Filing
Apr 08, 2025 3 Filing
Apr 04, 2025 PRE 14A Filing
Mar 27, 2025 4 Filing
Mar 27, 2025 4 Filing
Mar 27, 2025 4 Filing